Guys,
A10 day monotherapjy was never going to produce spectacular results.
That was not the intention.
Safety and proving antiviral activity was the aim.
Moving forward, with a prsxumed license to administer bit225 for 3 months in a capsule, does gilead or any other pharma see an opportunity to partner up In their future trials.
I bet yes as this may be the missing link in a HIV cur by targeting the re-infection cells that current drugs cannot.
ias 2013 conference, page-19
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
